Sensus Healthcare (SRTS)
(Delayed Data from NSDQ)
$6.44 USD
+0.06 (0.94%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $6.44 0.00 (0.00%) 7:40 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
SRTS 6.44 +0.06(0.94%)
Will SRTS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRTS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRTS
TransMedics Group, Inc. (TMDX) Hit a 52 Week High, Can the Run Continue?
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?
SRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sensus Healthcare, Inc. (SRTS) Recently Broke Out Above the 20-Day Moving Average
Sensus Healthcare (SRTS) is on the Move, Here's Why the Trend Could be Sustainable
Best Momentum Stocks to Buy for August 13th
Other News for SRTS
Sensus Healthcare: Recurring Revenue Initiatives Are Exciting
Sensus Healthcare, Inc. (SRTS) Q2 2024 Earnings Call Transcript
Sensus Healthcare: A Strong Buy on Robust Financials and Strategic Expansion
Sensus Healthcare: Strong Buy on Robust Growth and Innovative Revenue Strategies
Roth MKM Remains a Buy on Sensus Healthcare (SRTS)